trial · primary record
Disitamab Vedotin
Non-Muscle-Invasive Bladder Cancer (NMIBC)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 50 |
| Primary completion | 2027-04 |
| Primary endpoint | 1-year disease-free survival rate(1-year DFS rate) |
| Registry ID | NCT07646145 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:59:02.523Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07646145
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.